Dr Reddy’s Laboratories announced today that it has launched Ziprasidone Hydrochloride Capsules,a bioequivalent generic version of Geodon,in the US market.
The company launched Ziprasidone Hydrochloride capsules on March 2,following the approval by the United States Food and Drug Administration (USFDA),a company statement said.
The Geodon brand had US sales of approximately USD 1.34 billion for the twelve months ending December 2011,according to IMS Health,the statement said.
Dr Reddy’s offers a portfolio of products and services including APls,custom pharmaceutical services,generics,biosimilars,differentiated formulations and NCEs. The company’s major markets include India,USA,UK,Germany,Romania,Russia and CIS,Venezuela,South Africa,and New Zealand.